Biomarin Pharmaceutical INC BIOMARIN PHARMACEUTICAL ORD SHS
Biomarin Pharmaceutical INC BIOMA.../ US09061G1013 /
0HNC
|
2024-01-23 12:00:00 AM
|
Chg.
-
|
Volume |
Bid6:00:03 AM |
Ask6:00:03 AM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
94.04USD
|
-
|
14
Turnover: - |
-Bid Size: - |
-Ask Size: - |
13.49 bill.USD |
- |
79.62 |
Fundamentals
| |
FY 2023 |
Growth (1Y) |
| Per Share |
|
| Earnings per Share: |
0.89 USD |
17.11% |
| EPS Diluted: |
0.87 USD |
16.00% |
| Revenues per Share: |
12.82 USD |
14.11% |
| Book Value per Share: |
26.24 USD |
6.34% |
| Cash Flow per Share: |
0.84 USD |
-10.49% |
| Dividend per Share: |
- USD |
- |
| Total |
in mill. |
|
| Revenues: |
2,419.23 USD |
15.42% |
| Net Income: |
167.65 USD |
18.43% |
| Operating Cash Flow: |
159.26 USD |
- |
| Cash and Cash Equivalents: |
755.13 USD |
- |
Valuation Ratios
| |
Current |
Latest FY* |
| P/E Ratio: |
79.62 |
108.34 |
| P/S Ratio: |
5.53 |
7.52 |
| P/BV ratio: |
2.70 |
3.67 |
| P/CF Ratio: |
83.95 |
114.23 |
| PEG: |
4.65 |
6.33 |
| Earnings Yield: |
1.26% |
0.92% |
| Dividend Yield: |
- |
- |
| Market Capitalization |
|
| Market Capitalization: |
13.49 bill. USD |
18.19 bill. USD |
| Free Float Market Cap.: |
- USD |
- USD |
| Market Cap. / Employee: |
- USD |
- USD |
| Shares Outstanding: |
190.38 mill. |
|
Profitability
| Gross Profit Margin: |
78.72% |
| EBIT Margin: |
6.54% |
| Net Profit Margin: |
6.93% |
| Return on Equity: |
3.39% |
| Return on Assets: |
2.45% |
Financial Strength
| Liquidity I / Cash Ratio: |
0.64% |
| Liquidity II / Quick Ratio: |
1.18% |
| Liquidity III / Current Ratio: |
2.51% |
| Debt / Equity Ratio: |
0.22% |
| Dynam. Debt / Equity Ratio: |
1,186.78% |
Efficiency
| Employees: |
- |
| Personal Expenses / Employee: |
- USD |
| Revenues / Employee: |
- USD |
| Net Income / Employee: |
- USD |
| Total Assets / Employee: |
- USD |
| * Fiscal Year End: |
2023-12-31 |
| Accounting Standard: |
US GAAP |
